Studying Tumor Tissue Samples From Patients With Melanoma Who Have Undergone Sentinel Lymph Node Biopsy

Recruiting

You are on the General Public view
  • Source

    -
    Public Title Studying Tumor Tissue Samples From Patients With Melanoma Who Have Undergone Sentinel Lymph Node Biopsy
    Acronym Sorry, not currently available
    Source of Record URL http://clinicaltrials.gov/show/NCT00897481
  • Trial

    -
    Health Condition(s) or Problem Melanoma (Skin)
    Lay Summary RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help the study of cancer in the future. PURPOSE: This laboratory study is looking at tumor tissue samples from patients with melanoma who have undergone sentinel lymph node biopsy. (from ClinicalTrials.gov)
    Who can enter the trial DISEASE CHARACTERISTICS: - Confirmed diagnosis of cutaneous melanoma - Breslow thickness > 0.75 mm - Has undergone sentinel lymph node biopsy - No primary melanoma that has not originated in the skin - No multiple primary melanomas - Currently under clinical followup OR discharged from follow up within the past 3 months PATIENT CHARACTERISTICS: - No other malignancy except for nonmelanoma skin cancer or cervical carcinoma in situ PRIOR CONCURRENT THERAPY: - See Disease Characteristics
    Who cannot enter the trial DISEASE CHARACTERISTICS: - Confirmed diagnosis of cutaneous melanoma - Breslow thickness > 0.75 mm - Has undergone sentinel lymph node biopsy - No primary melanoma that has not originated in the skin - No multiple primary melanomas - Currently under clinical followup OR discharged from follow up within the past 3 months PATIENT CHARACTERISTICS: - No other malignancy except for nonmelanoma skin cancer or cervical carcinoma in situ PRIOR CONCURRENT THERAPY: - See Disease Characteristics
    What will happen Genetic; gene expression analysis; Genetic; mutation analysis; Other; diagnostic laboratory biomarker analysis; Other; immunohistochemistry staining method; Procedure; sentinel lymph node biopsy
    Primary aim Predictive model for sentinel lymph node biopsy positivity; Survival model for relapse; Genetic determinants in primary melanomas that predict a metastatic phenotype
    Secondary Aim Sorry, not currently available
    Participant Information Sheet Sorry, not currently available
    Website Sorry, not currently available
    Recruitment Status Recruiting
    Nation England
    Location Leeds
  • Contact

    -
    Contact for Public Queries Julia Newton Bishop, MD Study Chair Leeds Cancer Centre at St. James's University Hospital
    Contact for Scientific Queries Sorry, not currently available
Please note:
  1. The UKCTG information is designed to inform you of existing trials. If you wish to join a specific trial, you must discuss this with your own doctor who may decide to get in touch with the contact listed.
  2. The UKCTG is not responsible for the quality of the data displayed in the Gateway but can contact the data providers. Please contact us if you have any query regarding the quality of trial records.